Cepheid  

(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for Robert Easton�
43.55
-0.63 (-1.43%)
After Hours: 44.96 +1.41 (3.24%)
Apr 24, 5:06PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.60 - 44.96
52 week 30.95 - 55.89
Open 44.62
Vol / Avg. 960,590.00/756,445.00
Mkt cap 2.99B
P/E     -
Div/yield     -
EPS -0.40
Shares 68.56M
Beta 1.09
Inst. own 106%
Jul 14, 2014
Q2 2014 Cepheid Earnings Release (Estimated) Add to calendar
Apr 22, 2014
Cepheid Annual Shareholder Meeting
Apr 17, 2014
Q1 2014 Cepheid Earnings Conference Call
Apr 17, 2014
Q1 2014 Cepheid Earnings Release
Mar 5, 2014
Cepheid at Raymond James Financial Inc Institutional Investors Conference
Mar 3, 2014
Cepheid at Cowen Health Care Conference
Feb 13, 2014
Cepheid at Leerink Swann Global Healthcare Conference
Jan 30, 2014
Q4 2013 Cepheid Earnings Conference Call
Jan 30, 2014
Q4 2013 Cepheid Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -8.70% -4.48%
Operating margin -5.92% -3.99%
EBITD margin - 3.67%
Return on average assets -6.55% -4.95%
Return on average equity -11.69% -6.74%
Employees 1,200 -
CDP Score - -

Address

904 Caribbean Drive
SUNNYVALE, CA 94089
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market. The Company�s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company�s two principal systems are the GeneXpert and SmartCycler. The GeneXpert system, its primary offering in the Clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors� offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew D. Miller Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
David H Persing M.D., Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Age: 53
Bio & Compensation  - Reuters
Joseph H. Smith Executive Vice President - Business Development, General Counsel
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kerry J. Flom Ph.D. Executive Vice President, Chief Regulatory Officer
Age: 61
Bio & Compensation  - Reuters
Philippe Jacon Executive Vice President - International Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Warren C. Kocmond Jr. Executive Vice President - Global Operations
Age: 53
Bio & Compensation  - Reuters
James Post Executive Vice President - North American Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 65
Bio & Compensation  - Reuters